The FDA's rejection has led to a comprehensive investigation into Lykos' MDMA trials, with allegations that side effects were minimized and participants discouraged from reporting adverse reactions.
The approval process for the MDMA treatment has been severely disrupted by claims of misconduct, including sexual assault allegations and questions about the integrity of the trial data.
In response to the FDA's decision, Lykos has significantly downsized, laying off 75% of its workforce, and overhauling its leadership amid intensified scrutiny.
The journal's retraction of three MDMA studies from Lykos reflects significant ethical concerns over the company's clinical trial conduct, marking a troubling period for the experimental therapy.
Collection
[
|
...
]